MiR-6747-5p suppresses angiogenesis in esophageal squamous cell carcinoma by targeting EGFL6

  • Jiawen Huang Guangdong Province Engineering Research Center for Antibody Drug and Immunoassay, Department of Bioscience and Biotechnology, College of Life Science and Technology, Jinan University, Guangzhou 510632, China
  • Yuxin Xiao Guangdong Province Engineering Research Center for Antibody Drug and Immunoassay, Department of Bioscience and Biotechnology, College of Life Science and Technology, Jinan University, Guangzhou 510632, China
  • Cunjie Li Guangdong Province Engineering Research Center for Antibody Drug and Immunoassay, Department of Bioscience and Biotechnology, College of Life Science and Technology, Jinan University, Guangzhou 510632, China
  • Shifeng Liu Guangdong Province Engineering Research Center for Antibody Drug and Immunoassay, Department of Bioscience and Biotechnology, College of Life Science and Technology, Jinan University, Guangzhou 510632, China
  • Jieling Zhou Guangdong Province Engineering Research Center for Antibody Drug and Immunoassay, Department of Bioscience and Biotechnology, College of Life Science and Technology, Jinan University, Guangzhou 510632, China
  • Qifang Song Guangdong Province Engineering Research Center for Antibody Drug and Immunoassay, Department of Bioscience and Biotechnology, College of Life Science and Technology, Jinan University, Guangzhou 510632, China
  • Ting Wang Guangdong Province Engineering Research Center for Antibody Drug and Immunoassay, Department of Bioscience and Biotechnology, College of Life Science and Technology, Jinan University, Guangzhou 510632, China
  • Ning Deng Guangdong Province Engineering Research Center for Antibody Drug and Immunoassay, Department of Bioscience and Biotechnology, College of Life Science and Technology, Jinan University, Guangzhou 510632, China
DOI: https://doi.org/10.62617/mcb1047
Keywords: miR-6747-5p; EGFL6; esophageal squamous cell carcinoma; angiogenesis
Article ID: 1047

Abstract

Epidermal growth factor-like domain 6 (EGFL6) plays a crucial role in angiogenesis in various malignant tumors. This study aimed to screen microRNAs (miRNAs) targeting EGFL6 and explore their mechanisms in regulating angiogenesis in esophageal squamous cell carcinoma (ESCC) cells. After analyzing the miRNA expression profiles of ESCC and using the target prediction algorithm, we screened three miRNAs that could potentially target EGFL6. By dual luciferase reporter gene assay and western blot, we found that miR-6747-5p could directly target EGFL6 and down-regulate EGFL6 expression in ESCC cells. The results of clone formation, CCK-8, Transwell, wound healing, and endothelial cell tube formation assay showed that miR-6747-5p exerted a significant inhibitory effect on the proliferation, migration, invasion, and angiogenesis of ESCC cells. At the same time, we observed that the phosphorylation levels of AKT and MAPK were decreased, the epithelial-mesenchymal transition (EMT) related E-cadherin expression was downregulated while N-cadherin was upregulated, and the protein expression of the pro-angiogenic factors, including platelet-derived growth factor subunit B (PDGFB), fibroblast growth factor 2 (FGF2), and angiogenin (ANG) were inhibited transfected with miR-6747-5p mimics. Further studies showed that the overexpression vectors of EGFL6 transfected into ESCC cells could reverse the inhibitory effects induced by miR-6747-5p. These findings reveal that miR-6747-5p could target EGFL6 and inhibit tumor angiogenesis and ESCC progression. miR-6747-5p may be a promising biomarker for the anti-angiogenic treatment of ESCC.

References

1. Thrift A P. Global burden and epidemiology of Barrett oesophagus and oesophageal cancer[J]. Nature Reviews Gastroenterology & Hepatology, 2021.

2. Morgan E, Soerjomataram I, Rumgay H, et al. The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates from GLOBOCAN 2020[J]. Gastroenterology, 2022;163(3):649-658.e2.

3. Grover F L.Squamous cell carcinoma of the esophagus[J].Tex Med, 1984, 80(5):38-40.

4. Shah M A, Altorki N, Patel A A J A.Improving outcomes in patients with oesophageal cancer[J].Nature reviews. Clinical oncology, 2023, 20(6):390-407.

5. Li H, Yang X, Zhang A,et al.Age-period-cohort analysis of incidence, mortality and disability-adjusted life years of esophageal cancer in global, regional and national regions from 1990 to 2019[J].BMC Public Health, 2024, 24(1).

6. He S, Xu J, Liu X,et al.Advances and challenges in the treatment of esophageal cancer[J].Acta Pharmaceutica Sinica B, 2021;11(11):3379-3392.

7. Ooki A, Osumi H, Chin K,et al.Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma[J].Therapeutic Advances in Medical Oncology, 2023.

8. Hassanabad A F, Chehade R, Breadner D,et al.Esophageal carcinoma: Towards targeted therapies.[J].Cell Oncol (Dordr), 2020(2).

9. Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities[J]. Cell Mol Life Sci, 2020;77(9):1745-1770.

10. Wang K, Chen Q, Liu N,et al.Recent advances in, and challenges of, anti-angiogenesis agents for tumor chemotherapy based on vascular normalization.[J].Drug discovery today, 2021, 26(11):2743-2753.

11. Zhang B, Qi L, Wang X, et al. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma[J]. Cancer Commun (Lond), 2020;40(12):711-720.

12. Zhao J, Lei J, Yu J,et al.Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma[J].Investigational New Drugs, 2020, 38(2):500-506.

13. Li X, Zhou J, Wang X, et al. New advances in the research of clinical treatment and novel anticancer agents in tumor angiogenesis[J]. Biomed Pharmacother, 2023;163:114806.

14. Lopes-Coelho F, Martins F, Pereira S A,et al.Anti-Angiogenic Therapy: Current Challenges and Future Perspectives[J].International Journal of Molecular Sciences, 2021, 22(7):3765.

15. Kang J, Wang J, Tian J,et al.The emerging role of EGFL6 in angiogenesis and tumor progression[J].International Journal of Medical Sciences, 2020, 17(10):1320-1326.

16. Yeung G, Mulero J J, Berntsen R P,et al.Cloning of a novel epidermal growth factor repeat containing gene EGFL6: expressed in tumor and fetal tissues.[J].Genomics, 1999, 62(2):304-307.

17. Song X, Cheng X, Jin X,et al.EGFL6 promotes bone metastasis of lung adenocarcinoma by increasing cancer cell malignancy and bone resorption[J].Clinical & Experimental Metastasis, 2023, 40:357 - 371.

18. Sung TY, Huang HL, Cheng CC, et al. EGFL6 promotes colorectal cancer cell growth and mobility and the anti-cancer property of anti-EGFL6 antibody[J]. Cell Biosci, 2021;11(1):53.

19. Noh K, Mangala L S, Han H D,et al.Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis[J].Cell Reports, 2017, 21(10):2785-2795.

20. A M B, A A S P, A D M,et al.Micro-RNA: The darkhorse of cancer[J].Cellular Signalling, 2021.83:109995.

21. Shou Y, Wang X, Chen C, et al. Exosomal miR-301a-3p from esophageal squamous cell carcinoma cells promotes angiogenesis by inducing M2 polarization of macrophages via the PTEN/PI3K/AKT signaling pathway[J]. Cancer Cell Int, 2022;22(1):153.

22. Zhang C, Luo Y, Cao J, Wang X, Miao Z, Shao G. Exosomal lncRNA FAM225A accelerates esophageal squamous cell carcinoma progression and angiogenesis via sponging miR-206 to upregulate NETO2 and FOXP1 expression[J]. Cancer Med, 2020;9(22):8600-8611.

23. Zhu Y, Ma Y, Peng H, Gong L, Xiao M, et al. MiR-130b promotes the progression of oesophageal squamous cell carcinoma by targeting SASH1[J]. J Cell Mol Med, 2019;23(1):93-103.

24. Han L, Cui D, Li B, Xu WW, Lam AKY, et al. MicroRNA-338-5p reverses chemoresistance and inhibits invasion of esophageal squamous cell carcinoma cells by targeting Id-1[J]. Cancer Sci, 2019;110(12):3677-3688.

25. Bi Y, Guo S, Xu X,et al.Decreased ZNF750 promotes angiogenesis in a paracrine manner via activating DANCR/miR-4707-3p/FOXC2 axis in esophageal squamous cell carcinoma[J].Cell Death & Disease, 2020, 11(4).

26. Xu M, Zhang J, Lu X, Liu F, Shi S, et al. MiR-199a-5p-Regulated SMARCA4 Promotes Oral Squamous Cell Carcinoma Tumorigenesis[J]. Int J Mol Sci, 2023;24(5):4756.

27. Xu F, Wang Y, Ling Y, et al. dbDEMC 3.0: Functional Exploration of Differentially Expressed miRNAs in Cancers of Human and Model Organisms [J]. Genomics Proteomics Bioinformatics, 2022;20(3):446-454.

28. Dweep H, Gretz N, Sticht C. miRWalk database for miRNA-target interactions[J]. Methods Mol Biol, 2014;1182:289-305.

29. Loher P, Rigoutsos I. Interactive exploration of RNA22 microRNA target predictions[J]. Bioinformatics, (2012) 28:3322–3.

30. Sun H, Song X, Li C,et al.Humanized disulfide‐stabilized diabody against fibroblast growth factor‐2 inhibits PD‐L1 expression and epithelial‐mesenchymal transition in hepatoma cells through STAT3[J].IUBMB Life, 2023, 75(11):957-968.

31. Liu Z L, Chen H H, Zheng L L,et al.Angiogenic signaling pathways and anti-angiogenic therapy for cancer[J].Signal Transduction & Targeted Therapy, 2023, 8(1).198

32. Vimalraj S. A concise review of VEGF, PDGF, FGF, Notch, angiopoietin, and HGF signalling in tumor angiogenesis with a focus on alternative approaches and future directions[J]. Int J Biol Macromol, 2022;221:1428-1438.

33. Jiang X, Wang J, Deng X, et al. The role of microenvironment in tumor angiogenesis[J]. J Exp Clin Cancer Res, 2020;39(1):204.

34. Su Z, Li W, Lei Z, Hu L, Wang S, Guo L. Regulation of Angiogenesis by Non-Coding RNAs in Cancer[J]. Biomolecules, 2024;14(1):60.

35. Ding M H, Lozoya E G, Rico R N,et al.The Role of Angiogenesis-Inducing microRNAs in Vascular Tissue Engineering[J].Tissue engineering, Part A, 2020;26(23-24).

36. Nazari‐Khanamiri, Fereshteh, Abdyazdani N, Abbasi R,et al.Tumor cells‐derived exosomal noncoding RNAs in cancer angiogenesis: Molecular mechanisms and prospective[J].Cell Biochemistry & Function, 2023;41(8):1008-1015.

37. Shi Z Z, Wang W J, Chen Y X,et al. The miR-1224-5p/TNS4/EGFR axis inhibits tumour progression in oesophageal squamous cell carcinoma[J]. Cell Death & Disease, 2020;11(7):597.

38. Wang Y, Lu J, Chen L, et al. Tumor-Derived EV-Encapsulated miR-181b-5p Induces Angiogenesis to Foster Tumorigenesis and Metastasis of ESCC[J].. Mol Ther Nucleic Acids, 2020;20:421-437.

39. Shi S, Ma T, Xi Y.A Pan-Cancer Study of Epidermal Growth Factor-Like Domains 6/7/8 as Therapeutic Targets in Cancer[J].Frontiers in Genetics, 2020, 11:598743.

40. Zhu Z, Ni H, You B,et al.Elevated EGFL6 modulates cell metastasis and growth via AKT pathway in nasopharyngeal carcinoma[J].Cancer Medicine, 2018, 7(12):6281-6289.

41. Zhu W, Liu C, Lu T,et al.Knockout of EGFL6 by CRISPR/Cas9 mediated inhibition of tumour angiogenesis in ovarian cancer[J].Frontiers in Oncology, 2020;10:1451.

42. He G, Li W, Zhao W,et al.Formin‐like 2 promotes angiogenesis and metastasis of colorectal cancer by regulating the EGFL6/CKAP4/ERK axis[J].Cancer Science, 2023, 114(5):2014-2028.

43. Bai S, Ingram P, Chen YC, et al. EGFL6 Regulates the Asymmetric Division, Maintenance, and Metastasis of ALDH+ Ovarian Cancer Cells[J]. Cancer Res, 2016;76(21):6396-6409.

44. An J, Du Y, Fan X,et al.EGFL6 promotes breast cancer by simultaneously enhancing cancer cell metastasis and stimulating tumor angiogenesis[J].Oncogene, 2019;38(12):2123-2134.

45. Wu B, Zhang L, Yu Y,et al.miR-6086 inhibits ovarian cancer angiogenesis by downregulating the OC2/VEGFA/EGFL6 axis[J].Springer Science and Business Media LLC, 2020;11(5):345.

46. Fukuda T, Baba H, Okumura T, et al. miR-877-3p as a Potential Tumour Suppressor of Oesophageal Squamous Cell Carcinoma[J]. Anticancer Res, 2023;43(1):35-43.

47. Wei Q Y, Jin F, Wang Z Y,et al.MicroRNAs:A novel signature in the metastasis of esophageal squamous cell carcinoma[J].World Journal of Gastroenterology, 2024, 30(11):1497-1523.

48. Xiao Z, Zhao J, Ji G,et al.miR-493-5p Silenced by DNA Methylation Promotes Angiogenesis via Exosomes and VEGF-A-Mediated Intracellular Cross-Talk Between ESCC Cells and HUVECs[J].International Journal of Nanomedicine, 2024, 19:7165-7183.

Published
2025-01-16
How to Cite
Huang, J., Xiao, Y., Li, C., Liu, S., Zhou, J., Song, Q., Wang, T., & Deng, N. (2025). MiR-6747-5p suppresses angiogenesis in esophageal squamous cell carcinoma by targeting EGFL6. Molecular & Cellular Biomechanics, 22(2), 1047. https://doi.org/10.62617/mcb1047
Issue
Vol. 22 No. 2 (2025)
Section
Article

Copyright (c) 2025 Jiawen Huang, Yuxin Xiao, Cunjie Li, Shifeng Liu, Jieling Zhou, Qifang Song, Ting Wang, Ning Deng

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright on all articles published in this journal is retained by the author(s), while the author(s) grant the publisher as the original publisher to publish the article.

Articles published in this journal are licensed under a Creative Commons Attribution 4.0 International, which means they can be shared, adapted and distributed provided that the original published version is cited.